CapsoVision, Inc.
As of Oct 22, 2026, CapsoVision is in Stage 3, the topping phase, now in its first week (since Oct 21, 2026). It closed at $6.80, 52.8% below its 52-week high and above its 200-day average, which is falling.
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CV early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CV among Medical Devices20th of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
| …20 | CV | Stage 3 · wk 1 | 82 | +12.4% |
CapsoVision: quick answers
What stage is CapsoVision in?
As of Oct 22, 2026, CapsoVision (CV) is in Stage 3, the topping phase. It entered Stage 3 on Oct 21, 2026 and is in its first week there. What the four stages mean
Is CapsoVision in an uptrend?
Its uptrend has stalled. CapsoVision is in Stage 3, the topping phase that follows an advance. It trades 7.3% above its 200-day average, which is falling.
How far is CapsoVision from its 52-week high?
CapsoVision closed at $6.80 on Oct 22, 2026, 52.8% below its 52-week high of $14.42. Its 52-week low is $4.59.
How has CapsoVision performed over the past year?
As of Oct 22, 2026, CapsoVision is up 41.4% over the past year and down 33.6% so far in 2026.
Which sector and industry is CapsoVision in?
CapsoVision is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.